Previously considered to be rare, malignant pleural mesothelioma (MPM) is a highly aggressive tumor with an increasing incidence linked to asbestos exposure, its main etiological factor. MPM is also a very important issue because patients have usually a short survival (median <12 months) despite current treatments. Moreover an optimal treatment for MPM is not defined yet, even if ERS/ESTS experts recently provided clear and up-to-date guidelines on MPM management. These guidelines on chemotherapy and radiotherapy for mesothelioma, as well as new therapeutic developments, are presented in this chapter.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/978-3-642-10862-4_8 | DOI Listing |
Publication Analysis
Top Keywords
chemotherapy radiotherapy
4
radiotherapy mesothelioma
4
mesothelioma considered
4
considered rare
4
rare malignant
4
malignant pleural
4
pleural mesothelioma
4
mesothelioma mpm
4
mpm highly
4
highly aggressive
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!